Cencora, Inc. (COR) stock analysis
Healthcare · Medical Distribution
From the 10-K filed 2025-11-25
Business type: Franchise
How it makes money
Cencora generates most of its revenue by distributing brand, generic, and specialty pharmaceuticals to healthcare providers through its U.S. Healthcare Solutions segment.
Cencora's revenue comes primarily from U.S. human health pharmaceutical distribution, where it sells brand-name, specialty, and generic drugs to hospitals, pharmacies, and physician practices.
High-volume, low-margin brand and GLP-1 medications expand overall sales volume, while generic pharmaceuticals yield higher gross profit margins despite lower unit prices.
What protects it: the moat
Long-term primary distribution contracts and network integration, such as its Elevate Provider Network and Good Neighbor Pharmacy program, secure its provider relationships.
Cencora embeds itself into healthcare provider operations by acting as the primary drug supplier and offering specialized support programs like Elevate Provider Network and Good Neighbor Pharmacy.
These services provide purchasing scale, managed care network connections, and pharmacy management tools that bind independent pharmacies and health systems to its distribution platform.
What growth costs
Cencora spends capital acquiring physician management services and specialty platforms like Retina Consultants of America while upgrading distribution facility automation and enterprise systems.
Expanding high-margin adjacencies requires substantial cash outlays, as demonstrated by the acquisition of an 85% interest in Retina Consultants of America.
Additionally, maintaining operating efficiency requires ongoing investments in warehouse automation, IT infrastructure upgrades across global distribution networks, and supply chain traceability technology under federal mandates.
What could damage it
The non-renewal or unfavorable restructuring of key customer agreements, particularly with Walgreens Boots Alliance, would severely diminish distribution volume and operating profits.
Cencora relies heavily on major customer relationships, with Walgreens and Boots representing a quarter of fiscal 2025 revenue and more than a third of net receivables.
If WBA's new private equity owners alter strategic agreements, accelerate planned retail store closures, or fail to renew multi-year contracts, Cencora would face severe revenue loss and underutilized distribution capacity.
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.